Sight Sciences

What in the ophthalmic field is Sight Sciences the most excited about now?

 

At Sight Sciences, we are most excited about partnering with eyecare professionals to improve the lives of patients suffering from debilitating eye diseases. With our innovative glaucoma and dry eye technologies, we have the responsibility to help address the underlying causes of these diseases with safety and efficacy.

 

The introduction of minimally invasive glaucoma surgery (MIGS) has provided advancements in technology and surgical technique with unprecedented benefits to surgeons and patients. Our OMNI^® Surgical system, with the broadest FDA-cleared ab interno indication for use in adults with primary open-angle glaucoma, enables surgeons to address all three points of resistance in the conventional outflow system. OMNI can be used alone or in combination with cataract surgery. With its proven safety and efficacy, OMNI significantly expands the treatment armamentarium for millions of glaucoma patients. Our new SION™ Surgical Instrument features an innovative bladeless goniotomy technology designed to minimize tissue trauma.

 

In dry eye, our TearCare^® System targets obstructed meibomian glands, the underlying cause of evaporative dry eye. TearCare delivers the clinically proven time and temperature required to effectively liquefy meibum in a noninvasive, open-eye experience which is followed by a targeted manual expression.

 

In what area of ophthalmology do you think Sight Sciences is making a unique impact?

 

Our innovative technologies, designed to comprehensively treat the underlying causes of eye disease, drive our differentiation. This year, we will present compelling new clinical evidence to demonstrate further OMNI’s and TearCare’s excellent efficacy and patient outcomes. We have commissioned a study of more than 100,000 eyes using the American Academy of Ophthalmology’s IRIS Registry of real-world data to analyze post-surgical outcomes for the leading MIGS technologies in the United States. We believe the data will demonstrate better results in key outcomes with our OMNI technology. We also expect interim results from the SAHARA RCT, which intends to demonstrate superiority of the TearCare System versus Restasis^®.

 

What does pursuing excellence look like for Sight Sciences?

 

Our pursuit of excellence focuses on patient needs and protecting humanity’s most precious sense – sight. When I joined Sight Sciences in 2017, we were a company of 10 employees. Since then, we have built one of the fastest-growing companies in eyecare. Our team of highly talented and committed individuals share a common goal to transform care for dry eye and glaucoma. Our company is built upon a foundation of technological advancement, innovating best-in-class products, and our cultural pillars of passion, community, courage, and perseverance. Through our trusted partnership with eyecare professionals and patients, we Deliver the Power of Sight.